Midline and right frontal brain function as a physiologic biomarker of remission in major depression
Authors:
- Ian A. CookIan A. Cook
- Aimee M. HunterAHAimee M. Hunter
- Michelle AbramsMAMichelle Abrams
- Barbara SiegmanBSBarbara Siegman
- Andrew F. LeuchterALAndrew F. Leuchter
- 1 November 2009
- journal article
- research article
- Published by Elsevier in Psychiatry Research: Neuroimaging
- Vol. 174 (2) , 152-157
Abstract
No abstract availableKeywords
This publication has 64 references indexed in Scilit:
- Brain functional changes during placebo lead‐in and changes in specific symptoms during pharmacotherapy for major depressionActa Psychiatrica Scandinavica, 2009
- An analysis of functional neuroimaging studies of dorsolateral prefrontal cortical activity in depressionPsychiatry Research: Neuroimaging, 2006
- Neurophysiologic Correlates of Side Effects in Normal Subjects Randomized to Venlafaxine or PlaceboNeuropsychopharmacology, 2004
- The Burden of Major Depression Avoidable by Longer-term Treatment StrategiesArchives of General Psychiatry, 2004
- Psychosocial Disability Before, During, and After a Major DepressiveEpisodeArchives of General Psychiatry, 2004
- Depression: Perspectives from Affective NeuroscienceAnnual Review of Psychology, 2002
- Medication Treatment for the Severely and Persistently Mentally IllThe Journal of Clinical Psychiatry, 1999
- EEG Alpha Asymmetry, Depression, and Cognitive FunctioningCognition and Emotion, 1998
- Acute vs. chronic EEG effects in maprotiline- and in clomipramine-treated depressive inpatients and the prediction of therapeutic outcomeJournal of Affective Disorders, 1994
- Are there distinct biochemical subtypes of depression? EEG characteristics of clinically defined on-drug responders and non-respondersJournal of Affective Disorders, 1988